Association between admission systolic blood pressure and major adverse cardiovascular events in patients with acute myocardial infarction.
Pubmed ID: 32559257
Pubmed Central ID: PMC7304596
Journal: PloS one
Publication Date: 06/19/2020
Affiliation: Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hu'nan, China.
MeSH Terms: Humans, Male, Female, Aged, Middle Aged, Hypertension, Treatment Outcome, Blood Pressure, Myocardial Infarction, Patient Admission
Authors: Wang X, Xing Z, Pei J, Chen P, Hu X, Su W, Deng S
Cite As: Pei J, Wang X, Xing Z, Chen P, Su W, Deng S, Hu X. Association between admission systolic blood pressure and major adverse cardiovascular events in patients with acute myocardial infarction. PLoS One 2020 Jun 19;15(6):e0234935. doi: 10.1371/journal.pone.0234935. eCollection 2020.
BACKGROUND: Several studies have previously demonstrated that higher systolic blood pressure level means lower risk of adverse cardiovascular outcomes. However, there is a lack of further investigation into the nonlinear relationship between admission systolic blood pressure (SBP) and adverse outcomes of acute myocardial infarction (AMI) patients. OBJECTIVES: The aim of this study was to investigate the specific relationship between admission SBP and incidence of major adverse cardiovascular events (MACE) in 30 days for AMI patients. METHODS AND RESULTS: Using data from the ACS-QUIK trial, we analyzed 21,364 patients from Kerala, India. In univariate linear-regression model, the OR was 0.90 per 10mmHg, the confidence interval (CI) was 95% (0.87-0.92) and P < 0.0001. The generalized additive model (GAM) showed a nearly U-shaped curve between admission SBP and MACE. Using a two-piecewise linear regression model, we calculated an inflection point of 159 mmHg. We found that the higher admission SBP is associated with lower incidence of MACE of AMI patients. In addition, subgroups with different LVEF have distinct effects on blood pressure-related outcomes. Lower SBP has a greater risk when LVEF < 40%. CONCLUSION: The present study revealed the U-shaped relationship between admission SBP and the risk of adverse cardiovascular outcome. The admission SBP could be a marker to provide clinical assessment and treatment. TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02256657.